NEW YORK – Fresh off a $70 million Series C funding round, startup Mission Bio aims to further establish a name for itself in the biopharma space by mobilizing its Tapestri single-cell analysis platform for clinical cancer drug trials.
The South San Francisco-based firm will also use the funding to bolster efforts to develop customized quality control assays using its platform for biotech companies wishing to measure the efficacy of their cell and gene therapies.